Theriva Biologics Statistics
Total Valuation
TOVX has a market cap or net worth of $10.27 million. The enterprise value is -$156,221.
Important Dates
The last earnings date was Thursday, March 12, 2026, before market open.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TOVX has 45.89 million shares outstanding. The number of shares has increased by 800.56% in one year.
| Current Share Class | 45.89M |
| Shares Outstanding | 45.89M |
| Shares Change (YoY) | +800.56% |
| Shares Change (QoQ) | +202.54% |
| Owned by Insiders (%) | 1.63% |
| Owned by Institutions (%) | 3.63% |
| Float | 45.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.52 |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.74, with a Debt / Equity ratio of 0.17.
| Current Ratio | 1.74 |
| Quick Ratio | 1.69 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -137.82% and return on invested capital (ROIC) is -48.58%.
| Return on Equity (ROE) | -137.82% |
| Return on Assets (ROA) | -25.51% |
| Return on Invested Capital (ROIC) | -48.58% |
| Return on Capital Employed (ROCE) | -53.22% |
| Weighted Average Cost of Capital (WACC) | 5.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.58M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -81.80% in the last 52 weeks. The beta is 0.52, so TOVX's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | -81.80% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.32 |
| Relative Strength Index (RSI) | 65.24 |
| Average Volume (20 Days) | 16,763,019 |
Short Selling Information
The latest short interest is 6.12 million, so 13.33% of the outstanding shares have been sold short.
| Short Interest | 6.12M |
| Short Previous Month | 7.59M |
| Short % of Shares Out | 13.33% |
| Short % of Float | 13.55% |
| Short Ratio (days to cover) | 0.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.02M |
| Pretax Income | -23.74M |
| Net Income | -25.25M |
| EBITDA | -14.91M |
| EBIT | -15.02M |
| Earnings Per Share (EPS) | -$2.08 |
Full Income StatementBalance Sheet
The company has $13.06 million in cash and $2.63 million in debt, with a net cash position of $10.43 million or $0.23 per share.
| Cash & Cash Equivalents | 13.06M |
| Total Debt | 2.63M |
| Net Cash | 10.43M |
| Net Cash Per Share | $0.23 |
| Equity (Book Value) | 15.38M |
| Book Value Per Share | 0.43 |
| Working Capital | 7.45M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.67 million and capital expenditures -$35,000, giving a free cash flow of -$16.70 million.
| Operating Cash Flow | -16.67M |
| Capital Expenditures | -35,000 |
| Depreciation & Amortization | 108,000 |
| Net Borrowing | 1.44M |
| Free Cash Flow | -16.70M |
| FCF Per Share | -$0.36 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
